T. Rowe Price Associates
ATRA icon

T. Rowe Price Associates’s Atara Biotherapeutics ATRA Stock Holding History

T. Rowe Price Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-198,326
Closed -$3.44M – 2931
2024
Q1 		$3.44M Buy
198,326
+196,126
+8,915% +$3.48M ﹤0.01% 1336
2023
Q4 		$29K Hold
2,200
– – ﹤0.01% 2853
2023
Q3 		$82K Sell
2,200
-865
-28% -$38.5K ﹤0.01% 2697
2023
Q2 		$124K Buy
3,065
+70
+2% +$3.96K ﹤0.01% 2650
2023
Q1 		$218K Sell
2,995
-258
-8% -$25K ﹤0.01% 2486
2022
Q4 		$267K Sell
3,253
-1,025
-24% -$107K ﹤0.01% 2413
2022
Q3 		$405K Buy
4,278
+2,513
+142% +$282K ﹤0.01% 2231
2022
Q2 		$344K Buy
1,765
+618
+54% +$101K ﹤0.01% 2386
2022
Q1 		$266K Buy
1,147
+247
+27% +$78.7K ﹤0.01% 2597
2021
Q4 		$355K Sell
900
-469
-34% -$197K ﹤0.01% 2531
2021
Q3 		$613K Buy
1,369
+8
+0.6% +$2.87K ﹤0.01% 2280
2021
Q2 		$529K Buy
1,361
+195
+17% +$69.6K ﹤0.01% 2369
2021
Q1 		$419K Buy
1,166
+13
+1% +$5.75K ﹤0.01% 2446
2020
Q4 		$566K Buy
1,153
+564
+96% +$260K ﹤0.01% 2190
2020
Q3 		$191K Buy
+589
New +$201K ﹤0.01% 2433
2019
Q3 		– Sell
-10,609
Closed -$5.33M – 2521
2019
Q2 		$5.33M Sell
10,609
-59,461
-85% -$42M ﹤0.01% 1388
2019
Q1 		$69.6M Sell
70,070
-943
-1% -$876K 0.01% 742
2018
Q4 		$61.7M Buy
71,013
+339
+0.5% +$315K 0.01% 746
2018
Q3 		$73.1M Buy
70,674
+2,170
+3% +$2.12M 0.01% 773
2018
Q2 		$62.9M Buy
68,504
+786
+1% +$844K 0.01% 800
2018
Q1 		$66M Buy
+67,718
New +$61.7M 0.01% 776
2016
Q3 		– Sell
-1,070
Closed -$602K – 2530
2016
Q2 		$602K Buy
1,070
+606
+131% +$291K ﹤0.01% 1894
2016
Q1 		$221K Hold
464
– – ﹤0.01% 2269
2015
Q4 		$306K Sell
464
-1,152
-71% -$871K ﹤0.01% 2147
2015
Q3 		$1.27M Buy
+1,616
New +$1.97M ﹤0.01% 1640

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

T. Rowe Price Associates's ATRA Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 198,326 shares — an estimated $3.44M sold.

T. Rowe Price Associates first reported a position in ATRA in Q3 2015 and held it in 25 quarters. The position peaked at $73.1M in Q3 2018. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 198,326 Atara Biotherapeutics shares in Q2 2024, an estimated $3.44M.
  • T. Rowe Price Associates first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 25 quarters.
  • T. Rowe Price Associates's Atara Biotherapeutics position peaked at $73.1M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.